Biological properties of 8-methoxypyrimido [41, 51:4,5]thieno(2,3-b) quinoline-4(3H)-one, a new class of DNA intercalating drugs

Indian Journal of Medical Research

Volumn 119, Issue 5, 2004, Pages 198-205

  Gopal, Muttagi ^a   Shahabuddin, M S ^a  

^a KUVEMPU UNIVERSITY   (India)

Author keywords

Analgesic; Antiinflammatory; Antitumour activity; Cytotoxic activity; MPTQ

Indexed keywords

8 METHOXYPYRIMIDOL[4',5':4,5]THIENO(2,3 B)QUINOLINE 4(3H) ONE; ACETIC ACID; ACETYLSALICYLIC ACID; CARRAGEENAN; ELLIPTICINE; INTERCALATING AGENT; MORPHINE SULFATE; PHENYLBUTAZONE; TRYPAN BLUE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL STRAIN HL 60; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DOSE RESPONSE; DRUG DNA INTERACTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIFESPAN; MALE; MELANOMA B16; MOUSE; NONHUMAN; PAW EDEMA; PHYSICAL CHEMISTRY; RAT; SINGLE DRUG DOSE; TUMOR CELL LINE; TUMOR GROWTH;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INTERCALATING AGENTS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; QUINOLINES; RATS; RATS, WISTAR; THIOPHENES; TUMOR CELLS, CULTURED;

EID: 3042613603     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. 1:4,5]thieno(2,3-b)quinoline-4(3H -ones. J Chem Res 1988; 50: 537-51.
2. 1:4,5]thieno[2,3-b]quinolin-4-ones. Indian J Chem 1994; 33: 375-9.
3. Li LH, Cowie CH. Biochemical effects of ellipticine on leukemia L1210 cells. Biochem Biophys Acta 1976; 353: 375-84.
4. Gatto B, Capranico G, Palumbo M. Drugs acting on DNA topoisomerase: recent advances and future perspectives. Curr Pharm Design 1999; 5: 195-215.
5. 1:4,5]thieno(2,3-b quinoline-4(3H)-one antitumour drug and deoxyribonucleic acid. Proc Indian Acad Sci (Chem Sci) 2002; 114: 687-96.
6. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by vinca alkaloids. Cancer Res 1991; 51: 2212-22.
7. Peters KB, Brown MJ. Tirapazamine: A hypoxia activated topoisomerase II poison. Cancer Res 2002; 62: 5248-53.
8. Kruczynski A, Colpaert F, Tarayre JP, Mouillard P, Fahy J, Hill BT. Preclinical in vivo antitumour activity of vinflunine, a novel fluorinated vinca alkaloid. Cancer Chemother Pharmacol 1998; 41: 437-47.
9. Hendriks HR, Langdon S, Berger DP, Breistol K, Fiebig HH, Fodstad Ø. et al. Comparative antitumour activity of vinblastine isoleucinate and related vinca alkaloids in human tumour xenografts. Eur J Cancer 1992; 28: 767-73.
10. Winter CA, Risley EA, Nuss GW. Carrageenan induced oedema in hind paw of the rats an assay for antiinflammatory drugs. Proc Soc Exp Biol Med 1962; 111: 544-7.
11. Kavimani S, Vetrichelvan T, Ilango R, Jayakar B. Antiinflammatory activity of the volatile oil of Toddalia asiatica. Indian J Pharm Sci 1996; 58: 67-70.
12. D'Amour FE, Smith DL. A method for determining loss of pain sensation. J Pharmacol Exp Ther 1941; 72: 74-9.
13. Bianchi C, Francecshini J. Experimental observation of Haffner's method for testing analgesic drug. Br J Pharmacol 1954; 9: 280-4.
14. Langdon SP, Hendriks HR, Pratesi G, Berger DP, Fodstad Ø, Fiebig HH, et al. Preclinical phase II studies in human tumour xenografts: a European multicenter follow-up study. Ann Oncol 1994; 5: 415-22.
15. Venditti JM. Relevance of transplantable animal-tumour systems to the selection of new agents for clinical trials. In: Venditti JM, editor. Pharmacological basis of cancer therapy. Baltimore: Williams and Wilkins Company; 1975 p. 245-70.
16. Abraham EM, Magdalena MR, Jyoti PM, Richard HH, Valentino JS. Synthesis and evaluation of some water-soluble prodrugs and derivatives of Taxol with antitumour activity; J Med Chem 1992; 35: 145-51.
17. Kumar A, Verma RS, Saxena KK, Srivastava VK. 2, 10-disubstituted phenothiazine as antiinflammatory agents. J Indian Chem Soc 1994; 71 (Suppl 10): 641-2.
18. Larsen GL, Henson PM. Mediators of inflammation. Annu Rev Immunol 1986; 1: 335-9.
19. Vene J, Booting R. Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J 1987; 1: 89-96.
20. Schreinemachers DM, Everson RB. Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology 1994; 5: 138-46.
21. Ricchi P, Zarrilli R, di Palma A, Acquaviva AM. Nonsteroidal antiinflammatory drugs in colorectal cancer: from prevention to therapy. Br J Cancer 2003; 88: 803-7.
22. Bloom BM, Laubach GD. The relationship between chemical structure and pharmacological activity. Ann Rev Pharmacol 1962; 2: 75-82.